Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Surged 41.9% over 21 sessions and 17.7% on September 17. The Bunsen AI co-scientist launch, Bristol Myers Squibb deployment agreement, Tectora Therapeutics formation and upcoming clinical-data opportunities provide fresh catalysts alongside exceptional momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Operating Losses • Cash Burn SDGR's improving quarterly profitability and strong liquidity are encouraging, but persistent operating losses, negative cash flow, and weak annual returns make sustained profitability the key catalyst to watch.
Price Behavior
Key Price Behavior Insights: • Strong upward momentum • Overbought RSI • Recent profit-taking Support Level: $23.25–$23.93; stronger support $20.00–$20.75 Resistance Level: $30.24 SDGR is in a strong last-month uptrend but is overbought near $30.24, making consolidation or a pullback toward $23.25–$23.93 possible.
Sentiment & News
Key News Insights: • Partnership Pivot • Financial Improvement • Institutional Buying Schrödinger is pivoting toward partnerships and company creation while stronger finances, institutional buying, and stock momentum support a cautiously positive outlook.
AI Summary
SDGR is evolving into a capital-light computational drug-discovery platform, with Bunsen adoption and Tectora potentially converting scientific leadership into scalable software and partnership economics; however, the investment remains execution-dependent as persistent cash burn, declining deferred revenue, and a stretched valuation require clear proof of recurring commercial traction before the balance sheet erodes.
Description
Schrödinger, Inc. develops physics-based computational tools used to identify and design novel molecules for therapeutic and materials applications, and sells that software to customers in life sciences and industrial research. The company also operates a drug discovery unit that advances preclinical and clinical programs both internally and through collaborations, serving biopharmaceutical firms, industrial companies, academic institutions and government labs worldwide; it was incorporated in 1990 and is based in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 17 | Sep 24 | SDGR | Schrödinger, Inc. | Surged 41.9% over 21 sessions and 17.7% on September 17. The Bunsen AI co-scientist launch, Bristol Myers Squibb deployment agreement, Tectora Therapeutics formation and upcoming clinical-data opportunities provide fresh catalysts alongside exceptional momentum. | Closed | -2.6% |